Tyas Arum Widayati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tyas Arum Widayati has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Olga Chervova
UCL Cancer Institute, University College London , London WC1E 6DD
4 shared publications - Elizabeth Chernysheva
Department of Pathology and Biomedical Science, University of Otago
3 shared publications - Jadesada Schneider
Medical Genomics Lab, Cancer Institute, University College London
3 shared publications - Kseniia Panteleeva
Medical Genomics Lab, Cancer Institute, University College London
3 shared publications - Natalie Hrbkova
Medical Genomics Lab, Cancer Institute, University College London
3 shared publications - Stephan Beck
Medical Genomics, UCL Cancer Institute, University College London, London, UK
3 shared publications
Latest Publications
- Open Access
- 24 October 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1258648
Open access-enabled evaluation of epigenetic age acceleration in colorectal cancer and development of a classifier with diagnostic potential
Aberrant DNA methylation (DNAm) is known to be associated with the aetiology of cancer, including colorectal cancer (CRC). In the past, the availability of open access data has been the main driver of innovative method development and research training. However, this is increasingly being eroded by the move to controlled access, particularly of medical data, including cancer DNAm data. To rejuvenate this valuable tradition, we leveraged DNAm data from 1,845 samples (535 CRC tumours, 522 normal colon tissues adjacent to tumours, 72 colorectal adenomas, and 716 normal colon tissues from healthy individuals) from 14 open access studies deposited in NCBI GEO and ArrayExpress. We calculated each sample’s epigenetic age (EA) using eleven epigenetic clock models and derived the corresponding epigenetic age acceleration (EAA). For EA, we observed that most first- and second-generation epigenetic clocks reflect the chronological age in normal tissues adjacent to tumours and healthy individuals [e.g., Horvath (r = 0.77 and 0.79), Zhang elastic net (EN) (r = 0.70 and 0.73)] unlike the epigenetic mitotic clocks (EpiTOC, HypoClock, MiAge) (r < 0.3). For EAA, we used PhenoAge, Wu, and the above mitotic clocks and found them to have distinct distributions in different tissue types, particularly between normal colon tissues adjacent to tumours and cancerous tumours, as well as between normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals. Finally, we harnessed these associations to develop a classifier using elastic net regression (with lasso and ridge regularisations) that predicts CRC diagnosis based on a patient’s sex and EAAs calculated from histologically normal controls (i.e., normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals). The classifier demonstrated good diagnostic potential with ROC-AUC = 0.886, which suggests that an EAA-based classifier trained on relevant data could become a tool to support diagnostic/prognostic decisions in CRC for clinical professionals. Our study also reemphasises the importance of open access clinical data for method development and training of young scientists. Obtaining the required approvals for controlled access data would not have been possible in the timeframe of this study.
- 24 October 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1258648
Open AccessOpen access-enabled evaluation of epigenetic age acceleration in colorectal cancer and development of a classifier with diagnostic potential
Aberrant DNA methylation (DNAm) is known to be associated with the aetiology of cancer, including colorectal cancer (CRC). In the past, the availability of open access data has been the main driver of innovative method development and research training. However, this is increasingly being eroded by the move to controlled access, particularly of medical data, including cancer DNAm data. To rejuvenate this valuable tradition, we leveraged DNAm data from 1,845 samples (535 CRC tumours, 522 normal colon tissues adjacent to tumours, 72 colorectal adenomas, and 716 normal colon tissues from healthy individuals) from 14 open access studies deposited in NCBI GEO and ArrayExpress. We calculated each sample’s epigenetic age (EA) using eleven epigenetic clock models and derived the corresponding epigenetic age acceleration (EAA). For EA, we observed that most first- and second-generation epigenetic clocks reflect the chronological age in normal tissues adjacent to tumours and healthy individuals [e.g., Horvath (r = 0.77 and 0.79), Zhang elastic net (EN) (r = 0.70 and 0.73)] unlike the epigenetic mitotic clocks (EpiTOC, HypoClock, MiAge) (r < 0.3). For EAA, we used PhenoAge, Wu, and the above mitotic clocks and found them to have distinct distributions in different tissue types, particularly between normal colon tissues adjacent to tumours and cancerous tumours, as well as between normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals. Finally, we harnessed these associations to develop a classifier using elastic net regression (with lasso and ridge regularisations) that predicts CRC diagnosis based on a patient’s sex and EAAs calculated from histologically normal controls (i.e., normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals). The classifier demonstrated good diagnostic potential with ROC-AUC = 0.886, which suggests that an EAA-based classifier trained on relevant data could become a tool to support diagnostic/prognostic decisions in CRC for clinical professionals. Our study also reemphasises the importance of open access clinical data for method development and training of young scientists. Obtaining the required approvals for controlled access data would not have been possible in the timeframe of this study.
- Open Access
Open access-enabled evaluation of epigenetic age acceleration in colorectal cancer and development of a classifier with diagnostic potential
Aberrant DNA methylation (DNAm) is known to be associated with the aetiology of cancer, including colorectal cancer (CRC). In the past, the availability of open access data has been the main driver of innovative method development and research training. However, this is increasingly being eroded by the move to controlled access, particularly of medical data, including cancer DNAm data. To rejuvenate this valuable tradition, we leveraged DNAm data from 1,845 samples (535 CRC tumours, 522 normal colon tissues adjacent to tumours, 72 colorectal adenomas, and 716 normal colon tissues from healthy individuals) from 14 open access studies deposited in NCBI GEO and ArrayExpress. We calculated each sample’s epigenetic age (EA) using eleven epigenetic clock models and derived the corresponding epigenetic age acceleration (EAA). For EA, we observed that most first- and second-generation epigenetic clocks reflect the chronological age in normal tissues adjacent to tumours and healthy individuals (e.g. Horvath ( r = 0.77 and 0.79), Zhang EN ( r = 0.70 and 0.73)) unlike the epigenetic mitotic clocks (EpiTOC, HypoClock, MiAge) ( r < 0.3). For EAA, we used PhenoAge, Wu, and the above mitotic clocks and found them to have distinct distributions in different tissue types, particularly between normal colon tissues adjacent to tumours and cancerous tumours, as well as between normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals. Finally, we harnessed these associations to develop a classifier using elastic net regression (with lasso and ridge regularisations) that predicts CRC diagnosis based on a patient’s sex and EAAs calculated from histologically normal controls (i.e. normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals). The classifier demonstrated good diagnostic potential with ROC-AUC=0.886, which suggests that an EAA-based classifier trained on relevant data could become a tool to support diagnostic/prognostic decisions in CRC for clinical professionals. Our study also reemphasises the importance of open access clinical data for method development and training of young scientists. Obtaining the required approvals for controlled access data would not have been possible in the timeframe of this study.
Open AccessOpen access-enabled evaluation of epigenetic age acceleration in colorectal cancer and development of a classifier with diagnostic potential
Aberrant DNA methylation (DNAm) is known to be associated with the aetiology of cancer, including colorectal cancer (CRC). In the past, the availability of open access data has been the main driver of innovative method development and research training. However, this is increasingly being eroded by the move to controlled access, particularly of medical data, including cancer DNAm data. To rejuvenate this valuable tradition, we leveraged DNAm data from 1,845 samples (535 CRC tumours, 522 normal colon tissues adjacent to tumours, 72 colorectal adenomas, and 716 normal colon tissues from healthy individuals) from 14 open access studies deposited in NCBI GEO and ArrayExpress. We calculated each sample’s epigenetic age (EA) using eleven epigenetic clock models and derived the corresponding epigenetic age acceleration (EAA). For EA, we observed that most first- and second-generation epigenetic clocks reflect the chronological age in normal tissues adjacent to tumours and healthy individuals (e.g. Horvath ( r = 0.77 and 0.79), Zhang EN ( r = 0.70 and 0.73)) unlike the epigenetic mitotic clocks (EpiTOC, HypoClock, MiAge) ( r < 0.3). For EAA, we used PhenoAge, Wu, and the above mitotic clocks and found them to have distinct distributions in different tissue types, particularly between normal colon tissues adjacent to tumours and cancerous tumours, as well as between normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals. Finally, we harnessed these associations to develop a classifier using elastic net regression (with lasso and ridge regularisations) that predicts CRC diagnosis based on a patient’s sex and EAAs calculated from histologically normal controls (i.e. normal colon tissues adjacent to tumours and normal colon tissue from healthy individuals). The classifier demonstrated good diagnostic potential with ROC-AUC=0.886, which suggests that an EAA-based classifier trained on relevant data could become a tool to support diagnostic/prognostic decisions in CRC for clinical professionals. Our study also reemphasises the importance of open access clinical data for method development and training of young scientists. Obtaining the required approvals for controlled access data would not have been possible in the timeframe of this study.
- Open Access
Evaluation of Epigenetic Age Acceleration Scores and Their Associations with CVD-Related Phenotypes in a Population Cohort
We evaluated associations between nine epigenetic age acceleration (EAA) scores and 18 cardiometabolic phenotypes using an Eastern European ageing population cohort richly annotated for a diverse set of phenotypes (subsample, n = 306; aged 45–69 years). This was implemented by splitting the data into groups with positive and negative EAAs. We observed strong association between all EAA scores and sex, suggesting that any analysis of EAAs should be adjusted by sex. We found that some sex-adjusted EAA scores were significantly associated with several phenotypes such as blood levels of gamma-glutamyl transferase and low-density lipoprotein, smoking status, annual alcohol consumption, multiple carotid plaques, and incident coronary heart disease status (not necessarily the same phenotypes for different EAAs). We demonstrated that even after adjusting EAAs for sex, EAA–phenotype associations remain sex-specific, which should be taken into account in any downstream analysis involving EAAs. The obtained results suggest that in some EAA–phenotype associations, negative EAA scores (i.e., epigenetic age below chronological age) indicated more harmful phenotype values, which is counterintuitive. Among all considered epigenetic clocks, GrimAge was significantly associated with more phenotypes than any other EA scores in this Russian sample.
Open AccessEvaluation of Epigenetic Age Acceleration Scores and Their Associations with CVD-Related Phenotypes in a Population Cohort
We evaluated associations between nine epigenetic age acceleration (EAA) scores and 18 cardiometabolic phenotypes using an Eastern European ageing population cohort richly annotated for a diverse set of phenotypes (subsample, n = 306; aged 45–69 years). This was implemented by splitting the data into groups with positive and negative EAAs. We observed strong association between all EAA scores and sex, suggesting that any analysis of EAAs should be adjusted by sex. We found that some sex-adjusted EAA scores were significantly associated with several phenotypes such as blood levels of gamma-glutamyl transferase and low-density lipoprotein, smoking status, annual alcohol consumption, multiple carotid plaques, and incident coronary heart disease status (not necessarily the same phenotypes for different EAAs). We demonstrated that even after adjusting EAAs for sex, EAA–phenotype associations remain sex-specific, which should be taken into account in any downstream analysis involving EAAs. The obtained results suggest that in some EAA–phenotype associations, negative EAA scores (i.e., epigenetic age below chronological age) indicated more harmful phenotype values, which is counterintuitive. Among all considered epigenetic clocks, GrimAge was significantly associated with more phenotypes than any other EA scores in this Russian sample.
- Open Access
Evaluation of epigenetic age acceleration scores and their associations with CVD related phenotypes in a population cohort
Background Epigenetic age acceleration (EAA) is a measure that can be used to investigate the relationship between molecular, clinical and phenotypic data. However, which EAA score is best suited for which phenotype(s) is an open question. To address this issue, we have conducted a comprehensive comparison of multiple EAA scores using currently understudied Eastern European ageing population cohort (HAPIEE) which is richly annotated for diverse phenotypes. Our analysis was based on a subset (n = 306; aged between 45 and 69 years) of samples with available DNA methylation (DNAm) and phenotypic data. Results We calculated nine established EAA measures and performed statistical hypothesis testing to investigate associations between these scores and 18 cardiometabolic phenotypes. This was implemented by splitting the data into groups with positive and negative EAAs. We observed strong association between all EAA scores and sex, suggesting that in any analysis EAAs should be adjusted by sex. We found that some sex-adjusted EAA scores were significantly associated with several phenotypes (not necessarily the same phenotypes for different EAAs), indicating that some EAA scores are more phenotype-specific than others. We were able to replicate some of the associations in sex-specific subsets. Furthermore, the most of the EAA associations with cardio-vascular (except presence of Carotid Plaque (CP)) and lipids phenotypes were established in females but not males (and vice versa for CP and alcohol intake). This demonstrates that even after adjusting EAAs for sex, EAA-phenotype associations remain sex-specific, which should be taken into account in any downstream analysis involving EAAs. We observed that in some EAA-phenotype associations, negative EAA scores (i.e. epigenetic age below chronological age) indicated more harmful phenotype values, which is counter-intuitive. Overall, GrimAge was associated with more phenotypes than any of the other EAA scores. Conclusions EAAs are sex-specific and should be adjusted for sex in EAA-phenotypes association studies. Associations between EAAs and cardiometabolic phenotypes are sex-specific, even after adjusting for sex. For some EAAs, the direction of the association with phenotype is counter-intuitive. Our results can be used as a guidance on which EAA score to use for which phenotype(s).
Open AccessEvaluation of epigenetic age acceleration scores and their associations with CVD related phenotypes in a population cohort
Background Epigenetic age acceleration (EAA) is a measure that can be used to investigate the relationship between molecular, clinical and phenotypic data. However, which EAA score is best suited for which phenotype(s) is an open question. To address this issue, we have conducted a comprehensive comparison of multiple EAA scores using currently understudied Eastern European ageing population cohort (HAPIEE) which is richly annotated for diverse phenotypes. Our analysis was based on a subset (n = 306; aged between 45 and 69 years) of samples with available DNA methylation (DNAm) and phenotypic data. Results We calculated nine established EAA measures and performed statistical hypothesis testing to investigate associations between these scores and 18 cardiometabolic phenotypes. This was implemented by splitting the data into groups with positive and negative EAAs. We observed strong association between all EAA scores and sex, suggesting that in any analysis EAAs should be adjusted by sex. We found that some sex-adjusted EAA scores were significantly associated with several phenotypes (not necessarily the same phenotypes for different EAAs), indicating that some EAA scores are more phenotype-specific than others. We were able to replicate some of the associations in sex-specific subsets. Furthermore, the most of the EAA associations with cardio-vascular (except presence of Carotid Plaque (CP)) and lipids phenotypes were established in females but not males (and vice versa for CP and alcohol intake). This demonstrates that even after adjusting EAAs for sex, EAA-phenotype associations remain sex-specific, which should be taken into account in any downstream analysis involving EAAs. We observed that in some EAA-phenotype associations, negative EAA scores (i.e. epigenetic age below chronological age) indicated more harmful phenotype values, which is counter-intuitive. Overall, GrimAge was associated with more phenotypes than any of the other EAA scores. Conclusions EAAs are sex-specific and should be adjusted for sex in EAA-phenotypes association studies. Associations between EAAs and cardiometabolic phenotypes are sex-specific, even after adjusting for sex. For some EAAs, the direction of the association with phenotype is counter-intuitive. Our results can be used as a guidance on which EAA score to use for which phenotype(s).